Ethics and Human Experimentation
Indiana University School of Medicine, Indianapolis, Indiana. .Anesthesiology (Impact Factor: 6.17). 04/2011; 114(4):1001-2; author reply 1002-3. DOI: 10.1097/ALN.0b013e31820d84fb
Article: More on patient consent.Anesthesiology 01/1968; 29(3):602-3. DOI:10.1097/00000542-196805000-00051 · 6.17 Impact Factor
Article: Taming the Ketamine Tiger[Show abstract] [Hide abstract]
ABSTRACT: Pharmacologic actions of CI-581, a chemical derivative of phencyclidine, were determined in 20 volunteers from a prison population. The results indicate that this drug is an effective analgesic and anesthetic agent in doses of 1.0 to 2.0 mg per kilogram. With intravenous administration the onset of action is within 1 min and the effects last for about 5 to 10 min, depending on dosage level and individual variation. No tachyphylaxis was evident on repeat doses. Respiratory depression was slight and transient. Hypertension, tachycardia, and psychic changes are undesirable characteristics of the drug. Whether these can be modified by preanesthetic medication was not determined in this study. Recovery from analgesia and coma usually took place within 10 min, although from electroencephalographic evidence it may be assumed that subjects were not completely normal until after 1 to 2 h. No evidence of liver or kidney toxicity was obtained. CI-581 produces pharmacologic effects similar to those reported for phencyclidine, but of shorter duration. The drug deserves further pharmacologic and clinical trials. It is proposed that the words "dissociative anesthetic" be used to describe the mental state produced by this drug.Anesthesiology 09/2010; 113(3):678-84. DOI:10.1097/ALN.0b013e3181ed09a2 · 6.17 Impact Factor
- Anesthesiology 09/2010; 113(3):685-6. DOI:10.1097/ALN.0b013e3181f09404 · 6.17 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.